New drug shows promise for kidney disease patients with inflammation

NCT ID NCT05379829

First seen Oct 31, 2025 · Last updated Jun 05, 2026 · Updated 31 times

Summary

This study tested a drug called ziltivekimab in 24 Chinese adults with chronic kidney disease and signs of inflammation. Participants received either the drug or a placebo (dummy injection) three times over several weeks. The goal was to see how the drug moves through the body and if it is safe, with follow-up lasting about 6 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE AND SYSTEMIC INFLAMMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beijing Hospital

    Beijing, Beijing Municipality, 100730, China

  • Chinses People's Liberation Army General Hospital-Nephrology

    Beijing, Beijing Municipality, 100853, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100191, China

  • The First Affiliated Hospital Of Soochow University

    Suzhou, Jiangsu, 215006, China

  • The First Affiliated Hospital of Soochow University-Endocrinology

    Suzhou, Jiangsu, 215006, China

  • Zhongda Hospital Southeast University-Nephrology

    Nanjing, Jiangsu, 210009, China

  • Zhongda Hospital Southeast University-Neurology

    Nanjing, Jiangsu, 210009, China

Conditions

Explore the condition pages connected to this study.